AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

AstraZeneca has expanded its Bengaluru hub with a Rs 166 crore investment, creating 400 jobs to enhance R&D, global services, and AI innovation. The facility will house 1,300 employees, supporting ...

AstraZeneca has launched a new Global Hub in Bengaluru, investing Rs 166 crore for AI healthcare solutions. This move aims to advance R&D, IT, and digital health operations, creating 400 new jobs. The ...

AstraZeneca has launched a Phase I clinical study titled An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single ...

AstraZeneca, a global biopharmaceutical leader, on Thursday announced the expansion of its global hub in Bengaluru with an investment of ₹166 crore. The new facility will create 400 jobs, bringing the ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite ...